The company maintains a clean debt profile with a D/E ratio of 0.00, yet the accumulated deficit has ballooned to $303.4 million as of 2026Q1, reflecting the heavy cost of its strategic reorganization.
| Total Current Assets | 113.4M | 105.85M | 154.87M | 110.25M | 134.39M | 148.25M | 22M | 21.28M |
| Cash & Short-Term Investments | 109.56M | 101.08M | 150.92M | 106.8M | 123.57M | 136.48M | 20.49M | 21.22M |
| Cash Only | 8.36M | 35.69M | 87.23M | 93.11M | 43.59M | 46.92M | 20.49M | 21.22M |
| Short-Term Investments | 101.21M | 65.39M | 63.69M | 13.69M | 79.98M | 89.56M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 1.12M | 2.46M | 6.49M | 6.52M | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.84M | 4.77M | 256K | 112K | 3M | 852K | 11K | 35K |
| Total Non-Current Assets | 38.97M | 61.89M | 62.31M | 214K | 599K | 24.99M | 2.63M | 112K |
| Property, Plant & Equipment | 697K | 793K | 490K | 199K | 471K | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 287.94M | 59.57M | 61.61M | 0 | 0 | 24.92M | 0 | 0 |
| Other Non-Current Assets | 1.53M | 1.53M | 215K | 15K | 128K | 70K | 2.63M | 112K |
| Total Assets | 152.37M | 167.74M | 217.19M | 110.47M | 134.99M | 173.24M | 24.63M | 21.39M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Asset Growth % | -79.69% | -22.77% | 96.6% | -18.17% | -22.08% | 603.35% | 15.13% | - |
| Total Current Liabilities | 4.07M | 6.98M | 4.93M | 2.83M | 6.1M | 6.03M | 3.06M | 783K |
| Accounts Payable | 860K | 2.27M | 705K | 66K | 750K | 1.4M | 1.09M | 647K |
| Days Payables Outstanding | 3.92K | 8.54K | - | - | - | - | - | - |
| Short-Term Debt | 263K | 256K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.96M | 2.57M | 31K | 138K | 0 | 0 | 551K | 0 |
| Current Ratio | 27.86x | 15.16x | 31.41x | 38.92x | 22.04x | 24.58x | 7.18x | 27.18x |
| Quick Ratio | 27.86x | 15.16x | 31.41x | 38.92x | 22.04x | 24.58x | 7.18x | 27.18x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 216K | 285K | 375K | 37K | 180K | 7K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 1.27M | 285K | 375K | 15K | 180K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 22K | 0 | 7K | 0 | 0 |
| Total Liabilities | 4.29M | 7.27M | 5.31M | 2.87M | 6.28M | 6.04M | 3.06M | 783K |
| Total Debt | 479K | 541K | 532K | 349K | 480K | 0 | 0 | 0 |
| Net Debt | -7.88M | -35.14M | -86.7M | -92.76M | -43.1M | -46.92M | -20.49M | -21.22M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.13x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | 148.09M | 160.47M | 211.88M | 107.6M | 128.72M | 167.2M | 21.57M | 20.61M |
| Equity Growth % | -83.21% | -24.26% | 96.92% | -16.41% | -23.02% | 675.24% | 4.64% | - |
| Book Value per Share | 2.17 | 2.37 | 4.40 | 3.99 | 4.89 | 13.64 | 1.85 | 1.77 |
| Total Shareholders' Equity | 148.09M | 160.47M | 211.88M | 107.6M | 128.72M | 167.2M | 21.57M | 20.61M |
| Common Stock | 5K | 5K | 7K | 3K | 3K | 3K | 1K | 1K |
| Retained Earnings | -303.45M | -289.73M | -229.88M | -155.98M | -120.86M | -75.62M | -28.14M | -7.47M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 157K | 435K | 23K | -2K | -358K | -123K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial failure
According to quarterly financial statements, Climb Bio's total assets have declined from $226.0 million in 2024Q2 to $167.7 million by 2025Q4, reflecting a consistent contraction in the company's resource base as it funds clinical development without any offsetting revenue streams to replenish its balance sheet.
The downward trend in total assets suggests that the company is consuming its capital reserves at an unsustainable pace to support the budoprutug development program. Investors should monitor whether this trajectory forces a dilutive financing event sooner than the current cash position might otherwise imply.
As reported in recent filings, the company's cash and equivalents dropped from a peak of $223.1 million in 2024Q2 to just $35.7 million by 2025Q4, indicating a significant reduction in the liquidity buffer available to fund ongoing Phase 2 clinical trials for its lead asset.
While the current ratio remains elevated at 15.16, this metric is largely a function of low current liabilities rather than robust cash reserves. The rapid depletion of cash suggests that the company's operational runway is narrowing, which may necessitate a strategic pivot or capital raise in the near term.
Based on the company's reported figures, retained earnings have deteriorated to a deficit of $289.7 million as of 2025Q4, illustrating the cumulative impact of sustained R&D spending and the strategic reorganization costs incurred during the transition from Eliem Therapeutics to the current Climb Bio entity.
The persistent growth of the accumulated deficit highlights the high cost of clinical-stage biotechnology development and the lack of commercial revenue. This trend suggests that shareholder equity is being systematically eroded, placing increased pressure on the success of the budoprutug pipeline to justify the company's valuation.
Data from recent balance sheets indicates that the company's asset base is almost entirely composed of cash and minimal property, plant, and equipment, with no goodwill or intangible assets reported, which may mask the true economic cost of the Tenet Medicines acquisition and subsequent pipeline pivot.
The absence of significant intangible assets on the balance sheet warrants further investigation into how the acquisition of Tenet Medicines was accounted for and whether future impairments could arise. Investors should be cautious, as the lack of tangible assets means the company's value is tied exclusively to the unproven clinical potential of its lead therapeutic.
Quick answers to the most common questions about buying CLYM stock.
As of 2025, Climb Bio, Inc. (CLYM) had total assets of $167.7M including $105.8M in current assets.
Climb Bio, Inc. (CLYM) carries total debt of $0.5M, offset by $101.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Climb Bio, Inc. (CLYM) has total shareholders' equity (book value) of $160.5M ($2.37 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Climb Bio, Inc. (CLYM) reported a current ratio of 15.16x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.